Long-Term Management of Pulmonary Embolism: A Review of Consequences, Treatment, and Rehabilitation
- PMID: 36233833
- PMCID: PMC9571065
- DOI: 10.3390/jcm11195970
Long-Term Management of Pulmonary Embolism: A Review of Consequences, Treatment, and Rehabilitation
Abstract
The concept of pulmonary embolism is evolving. Recent and emerging evidence on the treatment of specific patient populations, its secondary prevention, long-term complications, and the unmet need for rehabilitation has the potential to change clinical practice for the benefit of the patients. This review discusses the recent evidence from clinical trials, observational studies, and guidelines focusing on anticoagulation treatment, rehabilitation, emotional stress, quality of life, and the associated outcomes for patients with pulmonary embolism. Guidelines suggest that the type and duration of treatment with anticoagulation should be based on prevalent risk factors. Recent studies demonstrate that an anticoagulant treatment that is longer than two years may be effective and safe for some patients. The evidence for extended treatment in cancer patients is limited. Careful consideration is particularly necessary for pulmonary embolisms in pregnancy, cancer, and at the end of life. The rehabilitation and prevention of unnecessary deconditioning, emotional distress, and a reduced quality of life is an important, but currently they are unmet priorities for many patients with a pulmonary embolism. Future research could demonstrate optimal anticoagulant therapy durations, follow-ups, and rehabilitation, and effective patient-centered decision making at the end of life. A patient preferences and shared decision making should be incorporated in their routine care when weighing the benefits and risks with primary treatment and secondary prevention.
Keywords: anticoagulation; bleeding; cancer-associated thrombosis; long-term management; patient preferences; pulmonary embolism; recurrence; rehabilitation; review.
Conflict of interest statement
A.A.H. reports research grants from The Danish Heart Foundation and The Novo Nordisk Foundation, consulting fees from Bayer and The Bristol-Myers Squibb-Pfizer Alliance, and speaker bureaus from Bayer, The Bristol-Myers Squibb-Pfizer Alliance, and MSD. N.R. has given talks about pulmonary embolism and physical rehabilitation on postgraduate courses for nurses and physicians within thrombosis, and has participated in the development and production of patient information materials on the same subject, which have both been sponsored by Bayer and Bristol Myers-Squibb, respectively. M.S. has received consulting and speaker fees from Bayer. P.B.N. has received consultant fees from Boehringer Ingelheim, grants, and consultant fees from Daiichi-Sankoy, grants from BMS/Pfizer, and grants and consultant fees from Bayer outside of the submitted work. IA has received speaking fees from Pfizer and Bayer. F.A.K. has received research support from Bayer, BMS, BSCI, MSD., Leo Pharma, Actelion, The Netherlands Organisation for Health Research and Development, The Dutch Thrombosis Association, The Dutch Heart Foundation and the Horizon Europe Program. A.G.O. and T.F.O. declare no conflict of interest.
References
-
- Barco S., Mahmoudpour S.H., Valerio L., Klok F.A., Münzel T., Middeldorp S., Ageno W., Cohen A.T., Hunt B.J., Konstantinides S.V. Trends in Mortality Related to Pulmonary Embolism in the European Region, 2000–2015: Analysis of Vital Registration Data from the WHO Mortality Database. Lancet. Respir. Med. 2020;8:277–287. doi: 10.1016/S2213-2600(19)30354-6. - DOI - PubMed
Publication types
LinkOut - more resources
Full Text Sources
